November 8, 2018: “Law, Finance, and Innovation in Pharmaceutical R&D”
- Esther S. Kim & Andrew W. Lo, The “New” Venture Philanthropy: A Case Study of the Cystic Fibrosis Foundation (Jul. 4, 2017 version)
- Adam Jorring, Andrew W. Lo, Tomas J. Philipson, Manita Singh, & Richard T. Thakor, Sharing R&D Risk in Healthcare via FDA Hedges (Working Paper; January 2018 Draft)
- Andrew W. Lo & Sourya V. Naraharisetti, Special Case Studies: New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, 12(1) Journal of Investment Management 4 (2014)
- Vivek Ramaswamy, Video of Remarks at the First Annual Roivant Pipeline Day
- Randall Smith, The Private Equity Firm that Quietly Profits on Top-Selling Drugs, New York Times, Jul. 8, 2017
- Richard T. Thakor, Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, & Andrew W. Lo, Just how good an investment is the biopharmaceutical sector?, 35(12) Nature Biotechnology (2017)
- Richard T. Thakor, Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, & Andrew W. Lo, Supplementary Information for: Just how good an investment is the biopharmaceutical sector? (Working Paper)
- Teresa Watanabe, UCLA will get hundreds of millions for rights to prostate cancer drug, Los Angeles Times (Mar. 4, 2016)
- Janet Woodcock, Expediting drug development for serious illness: Trade-offs between patient access and certainty, 15(3) Clinical Trials 230 (2018)